Scientific studies confirm: Targeted training affects the condition of cancer patients positively. But how strong can the strain be? How can the intensity of the training be adapted to the condition of oncological patients? Scientists at the National Center for Tumor Diseases (NCT) Heidelberg want to answer these questions. For the “TOP study” – Individual training control in oncological patients – participants are wanted. The Dietmar Hopp Foundation funds the project with 490,000 Euro.
The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), the Heidelberg University Hospital (UKHD) and the German Cancer Aid.
Cancer patients profit from physical activity during and after a therapy because the condition as well as the quality of life can increase. In order to work effectively, the training should be individually adapted. Based on current studies it is unclear how such training for oncological patients must be dosed. The TOP study “Individual training control for oncological patients” at the NCT Heidelberg studies how the program should be conducted. “We hope that patients will be able to improve their physical performance, quality of life and possibly even the course of the disease through the adapted exercise offers", explains Friederike Rosenberger who is leading the study together with Joachim Wiskemann. “We expect the training to reduce fatigue, anxiety and depression.”
Participation conditions
Prostate cancer patients and breast cancer patients who have completed their primary treatment within the last 12 months can participate in the study. The study participants can expect a 12-week free training program. At the beginning there is a stamina and a power test. The tests are followed by five units that train endurance or strength. Experienced sports scientists from the Oncological Sports and Exercise Therapy working group are guiding the patients. Using questionnaires, they also record how patients feel and how they respond to the strain. The Dietmar Hopp Foundation funds the TOP study with 490,000 euros.
Registration
Those who want to participate can contact the coordinators of the study via e-mail (top-studie@nct-heidelberg.de) or via telephone (06221/ 56 34250). In a personal conversation it will be decided if the patients fit the criteria for participation. If so, admission into the study program will follow.
Website:
https://www.nct-heidelberg.de/fileadmin/media/news/Meldungen/Dateien/NCT-Flyer_TopStudie.pdf
Accompanying picture free of charge:
https://www.nct-heidelberg.de/fileadmin/media/news/pressemitteilungen/NCT_PM_TOP.jpg
Instructions for use of image material for press releases:
Usage is free of charge. The NCT Heidelberg allows one-time use in connection with reporting on the topic of this press release. Please use credits as follows: "Copyright: NCT / Philip Benjamin ". A transfer of the image material to third parties is permitted only after prior consultation with the NCT Press Office (Tel. 06221 56 5930, E-Mail: friederike.fellenberg@nct-heidelberg.de). Use for commercial purposes is prohibited.
Press contacts:
Dr. Friederike Fellenberg
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 460
69120 Heidelberg
Tel.: +49 6221 56-5930
Fax: +49 6221 56-5350
E-Mail: friederike.fellenberg@nct-heidelberg.de
www.nct-heidelberg.de
Dr. Stefanie Seltmann
Deutsches Krebsforschungszentrum (DKFZ)
Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
69120 Heidelberg
Tel.: +49 6221 42-2854
Fax: +49 6221 42-2968
E-Mail: s.seltmann@dkfz.de
www.dkfz.de
Doris Rübsam-Brodkorb
Universitätsklinikum Heidelberg und Medizinische Fakultät der Universität Heidelberg
Presse- und Öffentlichkeitsarbeit
Im Neuenheimer Feld 672
69120 Heidelberg
Tel.: +49 6221 56-5052
Fax: +49 6221 56-4544
E-Mail: doris.ruebsam-brodkorb@med.uni-heidelberg.de
www.klinikum.uni-heidelberg.de
The National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. 2015 the NCT Heidelberg established a partner location in Dresden.
The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
The German Cancer Research Center (DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.
Heidelberg University Hospital and Medical Faculty Heidelberg
Heidelberg University Hospital is one of the most important medical centers in Germany; Heidelberg University's Medical Faculty is one of Europe's most prestigious biomedical research facilities. Their shared objective is the development of innovative diagnostics and treatments and their prompt implementation for the benefit of the patient. The hospital and faculty employ approximately 12 600 individuals and are involved in training and qualification. Every year approximately 66 000 patients are treated as inpatients or day patients in more than 50 specialized clinical departments with about 1 900 beds, with more than 1 million patients being treated as outpatients. The Heidelberg Curriculum Medicinale (HeiCuMed) is at the forefront of medical training in Germany. At present approx. 3500 prospective physicians are studying in Heidelberg.